Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features
暂无分享,去创建一个
Chang-ming Huang | C. Zheng | Ping Li | Zu-Kai Wang | Fuqiang Wang | Jia‐bin Wang | Jian-Xian Lin | Jian-Wei Xie
[1] Hidetaka Yamamoto,et al. Auxiliary diagnosis of subepithelial lesions by impedance measurement during endoscopic ultrasound guided fine-needle biopsy. , 2022, Gastrointestinal Endoscopy.
[2] Jianwen Xie,et al. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features , 2022, La radiologia medica.
[3] Bu-Lang Gao,et al. Malignancy risk of gastrointestinal stromal tumors evaluated with noninvasive radiomics: A multi-center study , 2022, Frontiers in Oncology.
[4] G. Ferrandina,et al. Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy , 2022, La radiologia medica.
[5] Andri Papakonstantinou,et al. Diagnosing gastrointestinal stromal tumors: The utility of fine‐needle aspiration cytology versus biopsy , 2022, Cancer medicine.
[6] L. Messerini,et al. Correlation of CT radiomic features for GISTs with pathological classification and molecular subtypes: preliminary and monocentric experience , 2022, La radiologia medica.
[7] Ying Wei,et al. Preoperative CT-Based Deep Learning Model for Predicting Risk Stratification in Patients With Gastrointestinal Stromal Tumors , 2021, Frontiers in Oncology.
[8] Minhong Wang,et al. CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study , 2021, Frontiers in Oncology.
[9] S. Sleijfer,et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] A. Yuille,et al. CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma. , 2021, AJR. American journal of roentgenology.
[11] A. Goldberg,et al. Mitotic count of fine needle aspiration material of gastrointestinal stromal tumours of the stomach underestimates actual mitotic count , 2021, Cytopathology : official journal of the British Society for Clinical Cytology.
[12] Oi Lei Wong,et al. Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic review. , 2021, Quantitative imaging in medicine and surgery.
[13] Minhong Wang,et al. Computed-Tomography-Based Radiomics Model for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors Preoperatively: A Multi-Classifier and Multicenter Study , 2021, Frontiers in Oncology.
[14] L. Meza-Zepeda,et al. Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach , 2021, Annals of Surgical Oncology.
[15] K. Marqueen,et al. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis , 2021, International journal of cancer.
[16] A. Marx,et al. Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy , 2021, Cancers.
[17] L. Doyle,et al. Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours , 2021, Histopathology.
[18] T. Niu,et al. Integrating tumor and nodal radiomics to predict lymph node metastasis in gastric cancer. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] R. Steenbakkers,et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. , 2020, Radiology.
[20] S. Lemeshow,et al. Assessing the goodness of fit of logistic regression models in large samples: A modification of the Hosmer‐Lemeshow test , 2020, Biometrics.
[21] J. Ren,et al. Computed tomography-based radiomics model for discriminating the risk stratification of gastrointestinal stromal tumors , 2020, La radiologia medica.
[22] Jing Zhang,et al. A clinical-radiomics nomogram for the preoperative prediction of lymph node metastasis in colorectal cancer , 2020, Journal of Translational Medicine.
[23] G. Mantese. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. , 2019, Current opinion in gastroenterology.
[24] Jing Lei,et al. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer , 2019, European Radiology.
[25] D. Dong,et al. Building CT Radiomics-Based Models for Preoperatively Predicting Malignant Potential and Mitotic Count of Gastrointestinal Stromal Tumors , 2019, Translational oncology.
[26] C. Raut,et al. OTT_A_180763 5123..5133 , 2019 .
[27] Dongsheng Gu,et al. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study , 2019, European Radiology.
[28] Wenbing Lv,et al. Radiomics Signature on Computed Tomography Imaging: Association With Lymph Node Metastasis in Patients With Gastric Cancer , 2019, Front. Oncol..
[29] C. Raut,et al. Defining Tumor Rupture in Gastrointestinal Stromal Tumor , 2019, Annals of Surgical Oncology.
[30] J. Qiao,et al. Gastrointestinal stromal tumors: a comprehensive review. , 2018, Journal of gastrointestinal oncology.
[31] Wenbing Lv,et al. Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer , 2018, EBioMedicine.
[32] N. Paragios,et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. , 2018, The Lancet. Oncology.
[33] T. Koga,et al. Current clinical management of gastrointestinal stromal tumor , 2018, World journal of gastroenterology.
[34] P. Parrilla,et al. Clinical and pathological features of "small" GIST (≤2 cm). What is their prognostic value? , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[35] V. Lemmens,et al. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era , 2018, The British journal of surgery.
[36] K. S. Hall,et al. Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study , 2018, Annals of Surgical Oncology.
[37] Andriy Fedorov,et al. Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.
[38] P. Lambin,et al. Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.
[39] L. Shen,et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[40] C. Antonescu,et al. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis , 2017, Annals of surgery.
[41] Stefan Leger,et al. Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.
[42] Huijun Hu,et al. Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour , 2016, European Radiology.
[43] M. McCarter,et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[44] Matthias Schmid,et al. Approaches to Regularized Regression – A Comparison between Gradient Boosting and the Lasso , 2016, Methods of Information in Medicine.
[45] Heikki Joensuu,et al. Gastrointestinal stromal tumour , 2013, The Lancet.
[46] H. Joensuu. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.
[47] Matthew P. Goetz,et al. NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .
[48] Prateek Prasanna,et al. Radiomics and radiogenomics in lung cancer: A review for the clinician. , 2018, Lung cancer.
[49] Paul J. Perry,et al. A Review for the Clinician , 2002 .